Trius Therapeutics Inc
Formerly RX3 Pharmaceuticals, Inc.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2011 | $30 M | No. 2 | $10 to $50 million | equity, options | SEC | |
| Nov 2009 | $19 M | No. 1 | $10 to $50 million | debt, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Trius Therapeutics Inc had revenue between $5 million and $25 million when it filed its newest notice of a funding round (Jun 2011).
SEC Form D (revenue range) · Jun 2011
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jun 2011
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
11 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| InterWest Management Partners IX, LLC | Fund or asset manager | not stated | not stated | Held Series A-2 and B preferred stock (Form 3, 2010) | SEC Form 3 |
| InterWest Partners IX, LP | Fund or asset manager | not stated | not stated | Held Series A-2 and B preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Kpcb Pandemic & Bio Defense Fund LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| KPCB PBD Associates, LLC | Other | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| KPCB PBD Founders Fund, LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Prism Venture Partners V-A LP | Venture capital | not stated | not stated | Held Series A-2 and B preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Prism Venture Partners V L.P. | Venture capital | not stated | not stated | Held Series A-2 and B preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Sofinnova Management VII, L.L.C. | Fund or asset manager | not stated | not stated | Held Series A-2 and B preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Sofinnova Venture Partners VII L.P. | Venture capital | not stated | not stated | Held Series A-2 and B preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Versant Side Fund III, L.P. | Fund or asset manager | not stated | not stated | Held Series A-2 and B preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Versant Venture Capital III, L.P. | Venture capital | not stated | not stated | Held Series A-2 and B preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 25 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Jeffrey Stein | Executive officer | Jun 2011 |
| John Finn | Executive officer | Jun 2011 |
| John P. Schmid | Executive officer | Jun 2011 |
| Kenneth S. Bartizal | Executive officer | Jun 2011 |
| Michael R. Morneau | Executive officer | Jun 2011 |
| Philippe S. Prokocimer | Executive officer | Jun 2011 |
| John Schmid | Executive officer | Nov 2009 |
| Kenneth G. Bartizal | Executive officer | Nov 2009 |
| Philippe G. Prokocimer | Executive officer | Nov 2009 |
| Brenden R. O'Leary | Director | Jun 2011 |
| Brian G. Atwood | Director | Jun 2011 |
| David S. Kabakoff | Director | Jun 2011 |
| Jeffrey Stein | Director | Jun 2011 |
| Karin S. Eastham | Director | Jun 2011 |
| Michael S. Powell | Director | Jun 2011 |
| Nina S. Kjellson | Director | Jun 2011 |
| Paul F. Truex | Director | Jun 2011 |
| Risa P. Stack | Director | Jun 2011 |
| Theodore R. Schroeder | Director | Jun 2011 |
| David Kabakoff | Director | Nov 2009 |
| Karin G. Eastham | Director | Nov 2009 |
| Michael G. Powell | Director | Nov 2009 |
| Nina G. Kjellson | Director | Nov 2009 |
| Paul Truex | Director | Nov 2009 |
| Risa Stack | Director | Nov 2009 |